SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Paimon SpaceX SPV Token (SPCX) offers investors exclusive access to SpaceX's growth potential through a British Virgin Islands Special Purpose Vehicle structure. Each token represents fractional ownership in the underlying SPV that invests in venture capital funds with SpaceX exposure. SPCX provides a unique opportunity to participate in the space industry's leading innovator. The token structure enables global qualified investors to access this premium late-stage venture equity that would typically be unavailable to most. SPCX is deployed on BNB Chain with plans for multi-chain expansion.

Paimon SpaceX SPV Token

Market speculation is intensifying around a potential SpaceX IPO under the ticker SPCX, with community members actively discussing valuation expectations and the potential for spillover momentum into aerospace industry proxies. Investors are heavily focused on the logistical details of the rumored listing timeline and the broader implications for liquidity across the sector.

Kura Sushi USA, Inc. engages in the operation of technology enabled Japanese restaurants. It offers a distinctive dining experience by serving authentic Japanese cuisine through engaging revolving sushi service models. The company was founded by Hajime Uba in 2008 and is headquartered in Irvine, CA.

Kura Sushi USA Inc - Ordinary Shares - Class A

Kura Sushi USA is trending as investors debate the impact of potential tariffs and recent volatility, while the community remains divided over its long-term growth versus valuation concerns. Discussions are heavily focused on the stock's historical tendency for sharp swings and the divergence between its rapid unit expansion and recent price performance.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin ($BNKR) is trending as the community highlights its role as infrastructure for autonomous on-chain AI agents within the Base ecosystem. Investors are actively discussing the token's accumulation phase, the potential for long-term utility-driven growth, and the ongoing development of its bot capabilities that facilitate on-chain DeFi transactions.

DocuSign, Inc. engages in the provision of cloud-based electronic signature solutions, which helps companies and individuals securely collect information, automate data workflows, and sign anything. The firm automates manual and paper-based processes allowing users to manage all aspects of documented business transactions including identity management, authentication, digital signature, forms and data collection, collaboration, workflow automation, and storage. Its products include eSignature, CLM, Gen for Salesforce, Document Generation, Standards-Based Signatures, Notary and Web Forms. The company was founded by Thomas H. Gonser and Court Lorenzini in 2003 and is headquartered in San Francisco, CA.

DocuSign Inc

DocuSign is trending as investors weigh strong earnings and share repurchases against cautious forward guidance, sparking debate over whether the firm's AI-driven Intelligent Agreement Management (IAM) platform can maintain a competitive moat. Community sentiment remains sharply divided between bulls betting on a valuation recovery fueled by solid fundamentals and bears concerned that AI disruption will commoditize the company's core signature services.

Tema ETF Trust - Tema Space Innovators ETF

The $NASA ETF is trending as investors rush to gain exposure to the highly anticipated SpaceX IPO through the fund's 10% stake in the private company, alongside other space infrastructure holdings. Community sentiment is overwhelmingly bullish, with retail investors comparing its potential trajectory to other high-volatility space plays and actively discussing the fund's asset growth as a proxy for the broader commercial space economy.

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Neogenomics Inc.

NeoGenomics is trending as investors respond to accelerating revenue growth, particularly in its high-margin NGS segment, and optimism surrounding the strategic integration of its cancer testing into the Epic Aura hospital network. The community is actively discussing the companys pivot toward becoming a precision oncology data powerhouse, with many bulls anticipating that strong fundamental execution and clinical footprint will drive a sustained re-rating.

Barclays Bank Plc engages in providing commercial banking services. It offers personal, premier, business, and corporate banking products and services to its customers. Its services include current accounts, savings, investments, mortgages, loans, insurance, credit cards, and online banking. The company was founded on October 4, 1971 and is headquartered in London, the United Kingdom.

Barclays Bank PLC - iPathÂ® Series B S&P 500Â® VIX Short-Term FuturesTM ETN

iPath S&P 500 VIX Short-Term Futures ETN

Investors are closely monitoring VXX as market participants debate whether recent volatility spikes signal an imminent correction or merely temporary hedging activity amidst elevated tech valuations. The community remains deeply divided, with some traders accumulating volatility hedges in anticipation of a potential market reversal, while others warn that shorting volatility products often leads to significant decay losses.

The World Collective Oil Reserve (WCOR) is a public-information program built on the Solana blockchain that mirrors the structure and reporting discipline of national strategic petroleum reserves. It applies established supply-security concepts — including import cover, shock response, emergency release protocols, and transparent stock reporting — to an open, permissionless environment. Data published through the program is drawn from public sources, with approximations clearly identified, and reserve records are maintained on-chain to support auditability, traceability, and independent verification. WCOR is presented as an informational and reference framework rather than a financial product, translating the reporting conventions of traditional strategic inventories into a blockchain-native format that any participant can inspect or cite.

World Collective Oil Reserve

WCOR is experiencing a surge in social media attention as investors speculate on its growth potential, though community members remain divided between excitement over recent gains and concerns regarding its status as a high-risk meme coin. Discussion is heavily focused on technical challenges and confusion surrounding the token's availability across different blockchain networks and trading platforms.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

The Grayscale Bitcoin Mini Trust is currently trending as community discussions remain heavily focused on Bitcoin's broader price volatility, institutional accumulation strategies by major holders, and ongoing geopolitical tensions in the Middle East impacting market sentiment. Investors are actively debating the potential for a breakout toward higher price levels versus concerns over liquidity squeezes and macroeconomic uncertainty.

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Pulse Biosciences Inc

Pulse Biosciences is trending due to heightened investor enthusiasm surrounding its proprietary Nanosecond Pulsed Field Ablation technology, which is being positioned as a potential breakthrough in cardiac and soft tissue treatment. The community is actively discussing the stock's clinical study milestones, aggressive insider buying by company leadership, and potential for a future buyout or strategic partnership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>AKAN is also on track for its best week ever with gains of 300% so far.</li><li>Investor sentiment across cannabis stocks improved after the U.S. Justice Department moved state-regulated marijuana toward Schedule III.</li><li>AKAN’s rally was amplified by its tiny public float of about 534,420 shares, following multiple reverse stock splits.</li></ul>Shares of Akanda Corp. (AKAN) delivered one of the biggest rallies in April among cannabis stocks, rocketing 1,700% and sharply outperforming peers as traders targeted the micro-float stock during a policy-driven sector rebound.<a href="https://stocktwits.com/symbol/AKAN">AKAN stock</a> outperformed cannabis peers, including&nbsp;<a href="https://stocktwits.com/symbol/TCNNF">Trulieve Cannabis (TCNNF)</a>, up 94%;&nbsp;<a href="https://stocktwits.com/symbol/CGC">Canopy Growth Corp. (CGC)</a>, up 30%;&nbsp;<a href="https://stocktwits.com/symbol/IGC">IGC Pharma (IGC)</a>, up 25%; and&nbsp;<a href="https://stocktwits.com/symbol/ACB">Aurora Cannabis (ACB)</a>, up 12%, over the past month. AKAN is also poised to log its best week ever,&nbsp;having more than quadrupled as of Thursday’s close.&nbsp;<img src="https://news.stocktwits-cdn.com/koyfin_20260501_083616528_png_777b15d360.webp" alt="koyfin_20260501_083616528.png"><h2 class="st-heading-2">Tiny Float, Higher Buzz For AKAN</h2>Investor sentiment for cannabis stocks got a boost after the U.S. government moved state-regulated marijuana from Schedule I toward Schedule III, pushing increased medical research access, tax treatment clarity, and regulatory legitimacy.The change revived optimism across the medical cannabis sector, with traders rotating into smaller stocks, which have exposure to future regulatory tailwinds. Akanda had previously welcomed U.S. rescheduling efforts in December, keeping the company relevant in the segment.The company operates a hemp platform focused on expanding access to medicinal-grade cannabis, CBD, and wellness products across legal markets. THC, or tetrahydrocannabinol, is the part of cannabis that produces the “high” and is therefore more tightly regulated, while CBD, or cannabidiol, does not cause intoxication and is widely used in medical and wellness treatments.&nbsp;The company implemented a 1-for-3.125 reverse stock split last year, followed by a more recent 1-for-5 reverse stock split in January. A further reverse split adjustment last month reduced its total float to 534,420 shares. Short levels for the stock currently stand at 4.7%, its highest levels in four months.&nbsp;Meanwhile, cannabis peers such as TLRY have a float of 119.28 million shares, CGC about 380.82 million, and CRON nearly 379.05 million. The comparatively tiny supply made AKAN shares more sensitive to buying pressure amid April’s cannabis rally.<h2 class="st-heading-2">Canada Cultivation Plans Take Root</h2>Akanda’s main cannabis asset is its Gabriola Island cultivation site in British Columbia, where the company currently operates under a hemp cultivation license, while working toward a full THC cultivation license covering cannabis flower and derivative products. In October, the company extended its option on the property for an additional two years.The pot firm has also been evaluating Health Canada-aligned security infrastructure requirements, including improved perimeter controls, surveillance systems, access management, and secure storage measures needed in licensing inspections for THC and CBD activities. Commercial THC production has not yet begun at the site.Akanda also exited its earlier African cultivation exposure after operations at its former unit in Lesotho ceased following an unauthorized liquidation ordered by the High Court of Lesotho in 2022, after which Akanda moved away from the region. It later discontinued operations at its Canmart distribution unit in the UK last year, citing licensing renewal costs and litigation exposure that outweighed expected near-term revenues.<h2 class="st-heading-2">Telecom Pivot Adds A Safety Net</h2>Akanda has also been gradually refocusing its strategy more heavily on Canada and Europe, while building a parallel telecommunications infrastructure platform through its unit, First Towers &amp; Fiber, in Mexico.&nbsp;As part of the pivot, the company has been expanding its dark-fiber network footprint across Central Mexico, including a recent addition of about 200 kilometers of infrastructure, which is expected to generate $2 million in contracted cash flow over 10 years. The move into telecom has added a source of contract-based income alongside Akanda’s medical cannabis business, providing investors with a potential hedge against the typical volatility in pure-cannabis companies.&nbsp;<h2 class="st-heading-2">How Do Retail Traders Feel About AKAN?</h2>On Stocktwits, retail sentiment for AKAN was ‘extremely bullish’ amid an eye-watering 231,800% surge in message volumes over the past month.<figure class="image"><img src="https://news.stocktwits-cdn.com/akan_ss_png_05e51e83c2.webp" alt="akan ss.png" width="974" height="140"><figcaption>AKAN sentiment and message volume as of April 30 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Stinkypoopypants/message/651947797">said</a>, “This is a low float that can run as high as it’s pushed. Shorts will have to cover at some point. Yes it will go down but the real question is how high can we push it?”<stembedurl>https://stocktwits.com/Stinkypoopypants/message/651947797</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/_MarginOfSanity_/message/651968893">said</a>, “Fundamentals don’t matter in a short squeeze. It’s just math. Limited supply meets infinite demand.”<stembedurl>https://stocktwits.com/_MarginOfSanity_/message/651968893</stembedurl>AKAN stock has jumped 376% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/asts-rklb-fly-lunr-stocks-rally-fcc-satellite-broadband-spectrum-rule/cZQNqL1ReIK">ASTS, RKLB, FLY, LUNR Stocks Rally As FCC Opens Door To Faster Satellite Broadband Networks</a>

AKAN stock has jumped 376% over the past year. Photo credit: Getty Images

AKAN Stock Leaves Cannabis Peers In The Smoke With A Stunning 1,700% Rally In April — What’s Fueling The Run?

The company’s primary cannabis asset remains its Gabriola Island cultivation site in British Columbia, where it operates under a hemp license.

Equity

<ul class="summary-bullets"><li>The change does not legalize marijuana but reduces regulatory hurdles and offers tax relief for licensed operators.</li><li>Trump has earlier framed the move as a step toward supporting medical research, while clarifying that it does not legalize recreational use.</li><li>The DOJ is updating procedures to speed up the rulemaking process needed to move marijuana from Schedule I to Schedule III.</li></ul>Shares of Tilray (TLRY), Canopy Growth (CGC), Aurora Cannabis (ACB), and IGC Pharma Inc (IGC) remained in focus after the U.S. Department of Justice formally moved to reclassify state-licensed medical marijuana as a less dangerous drug, four months after President Donald Trump signed an executive order to shift it from Schedule I to Schedule III.After rallying in the previous session and gaining in pre-market trading on Thursday, the stocks fell in morning trade. At the time of writing, TLRY, CGC, ACB and IGC fell between 2-5%.&nbsp;Meanwhile, AdvisorShares Pure US Cannabis ETF (MSOS) fell 5.5%.<h2 class="st-heading-2">DOJ To Update Rulemaking Processes For Reclassification</h2>While the change does not legalize marijuana, it reduces regulatory hurdles, offers tax relief for licensed operators, and makes research easier. Schedule III drugs are considered to have a moderate to low risk of dependence. Trump has earlier framed the move as a step toward supporting medical research, while clarifying that it does not legalize recreational use.“This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information,”&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.justice.gov/opa/pr/justice-department-places-fda-approved-marijuana-products-and-products-containing-marijuana">said</a> Todd Blanche, acting Attorney General, in a statement.Separately, the Justice Department said it is updating procedures to speed up the rulemaking process needed to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. The move is expected to expand access to medical treatments and support research, while also strengthening the legal framework for medical marijuana programs across dozens of U.S. states.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits for TLRY, CGC, ACB, and IGC turned ‘extremely bullish,’ amid ‘extremely high’ message volumes.One user said, “The weed industry is reborn.”<stembedurl>https://stocktwits.com/Lando_Calrissian/message/651131346</stembedurl>Another user said Tilray will be the “king in the U.S. cannabis market.”<stembedurl>https://stocktwits.com/Rumsen/message/651070434</stembedurl>Meanwhile, shares of nano-cap Akanda Corp. (AKAN)&nbsp;climbed 6% higher,&nbsp;extending a stunning 215% surge from the previous session, with investors and traders debating whether the explosive rally is driven by cannabis reclassification optimism or the stock’s low float.Message volumes on the Stocktwits platform for the stock surged by around 48,000% over a 24-hour period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Legalized Marijuana In Canada (Photo by Lane Turner/The Boston Globe via Getty Images)

TLRY, CGC, ACB, MSOS Pare Early Gains After Marijuana Reclassification: Retail Says ‘Weed Industry Is Reborn’

The U.S. Department of Justice formally moved to reclassify state-licensed medical marijuana as a less dangerous drug, four months after President Donald Trump signed an executive order.

<ul class="summary-bullets"><li>In December, Trump signed an executive order directing the reclassification of marijuana from a Schedule I to a Schedule III drug in the same category as Tylenol with codeine.</li><li>During a separate Oval Office signing ceremony on psychedelics research earlier this month, Trump directly addressed delays in his own rescheduling directive, saying his administration was “slow-walking.”</li><li>A Schedule I drug classification is reserved for substances deemed to have high abuse potential and no accepted medical use such as heroin and LSD.</li></ul> The Trump administration is reportedly slated to move to reclassify marijuana as soon as Wednesday.Axios <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.axios.com/2026/04/22/trump-marijuana-rule-change">reported</a> of the upcoming move, citing an administration official. &nbsp;Shares of Tilray (TLRY) traded 13% higher at the time of writing. Other publicly traded companies in the space including Aurora Cannabis (ACB), Canopy Growth (CGC), and&nbsp; IGC Pharma Inc (IGC) jumped 10%, 20% and 6%, respectively. AdvisorShares Pure US Cannabis ETF (<a href="https://stocktwits.com/symbol/MSOS">MSOS</a>), meanwhile, rallied 23% higher.In December, Trump signed an executive order directing the reclassification of marijuana from a Schedule I to a Schedule III drug in the same category as Tylenol with codeine. The order directed Attorney General to expedite the federal reclassification process through the Drug Enforcement Administration. Trump framed the move as focused on recognizing legitimate medical uses and accelerating research, while explicitly stating it does not legalize recreational marijuana.During a separate Oval Office signing ceremony on psychedelics research earlier this month, Trump directly addressed delays in his own rescheduling directive, saying his administration was “slow-walking.”A Schedule I drug classification is reserved for substances deemed to have high abuse potential and no accepted medical use such as heroin and LSD.The Trump administration is expected to classify marijuana as a Schedule III substance, indicating that it has a lesser potential for abuse and is allowed for use in specific medical treatments, but can also create risks of physical or psychological dependence.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TLRY and CGC are trending in the ‘extremely bullish’ territory, coupled with ‘high’ message volume.While <a href="https://stocktwits.com/symbol/TLRY">TLRY stock</a> has gained 70% over the past 12 months, <a href="https://stocktwits.com/symbol/CGC">CGC</a> has gained 16%.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rivian-stock-defies-tornado-setback-with-r2-production-kickstart/cZBBvT3ReGy">RIVN Stock Defies Tornado Setback With R2 Production Kickstart</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cannabis plants grow in the greenhouse at Vireo Health's medical marijuana cultivation facility, August 19, 2016 in Johnstown, New York. (Photo by Drew Angerer/Getty Images)

TLRY, CGC, IGC Stocks Light Up On Trump Pot Reclassification Hopes This Week  

Axios reported on Wednesday, citing an administration official, that the Trump administration is slated to reclassify marijuana as soon as Wednesday. 

electroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates

electroCore (ECOR) delivered earnings and revenue surprises of +1.45% and -0.18%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +180.75% and +147.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Merck KGaA (MKKGY) Lags Q4 Earnings Estimates

Merck KGaA (MKKGY) delivered earnings and revenue surprises of -40.43% and +0.69%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates

IGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of 0.00% and -56.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of +31.58% and +0.74%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates

Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +43.48% and -77.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of +233.33% and +2.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

Current Price	$0.286
Prev Close	$0.299
Open	$0.2941
Dividend Yield	0.00%
50-Day Moving Average	$0.2964
Beta	0.59
Avg. Volume	2.48M
PE Ratio	-4.63

52-Week High	$0.4985
52-Week Low	$0.242
Market Capitalization	$28.26M
EPS (Annual)	-$0.0931
Price to Book	3.66
Revenue Per Employee	$18,157.14

IGC
IGC Pharma Inc

Feed

News

Sentiment

Fundamentals

Info

Latest IGC News

IGCIGC Pharma Inc